Vincent CHUNG | City of Hope National ...

Dr. Vincent Chung, MD

Claim this profile

City of Hope Medical Center

Expert in Pancreatic Cancer
Studies Cancer
21 reported clinical trials
33 drugs studied

About Vincent Chung, MD

Education:

  • Earned an MD from the University of Tennessee Health Science Center College of Medicine, class of 1998.

Experience:

  • Completed an Internship and Residency in Internal Medicine at California Pacific Medical Center.
  • Undertook a Fellowship in Hematology and Medical Oncology at Los Angeles County-Harbor-UCLA Medical Center.
  • Served as Chief Resident at California Pacific Medical Center.
  • Board-certified in Internal Medicine and Medical Oncology.
  • Affiliated with City of Hope's Helford Clinical Research Hospital, specializing in Medical Oncology.

Area of expertise

1

Pancreatic Cancer

Global Leader

Vincent Chung, MD has run 14 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
ctDNA positive
NRAS positive
2

Cancer

Vincent Chung, MD has run 5 trials for Cancer. Some of their research focus areas include:

NTRK1 positive
PD-L1 positive
ctDNA positive

Affiliated Hospitals

Image of trial facility.

City Of Hope Medical Center

Image of trial facility.

City Of Hope

Clinical Trials Vincent Chung, MD is currently running

Image of trial facility.

Gemcitabine + Leflunomide

for Pancreatic Cancer

This phase Ib trial tests the safety, side effects, and best dose of leflunomide in combination with gemcitabine in treating patients with pancreatic cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and cannot be removed by surgery (unresectable). Improving the effectiveness of gemcitabine without increasing side effects could lead to a greater impact for pancreatic cancer patients' survival and quality of life. Gemcitabine is commonly used as a first-line chemotherapy treatment for pancreatic cancer. Leflunomide is a drug approved for use against rheumatoid arthritis that is being looked at as a cancer treatment option. It has shown promising results when combined with gemcitabine. Giving gemcitabine in combination with leflunomide may be safe and effective in treating patients with advanced unresectable pancreatic cancer.

Recruiting

1 award

Phase 1

8 criteria

Image of trial facility.

Peposertib + Radiation Therapy

for Pancreatic Cancer

This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and/or more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer.

Recruiting

0 awards

Phase 1 & 2

3 criteria

More about Vincent Chung, MD

Clinical Trial Related

3 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Vincent Chung, MD has experience with

  • Pembrolizumab
  • Lenvatinib Mesylate
  • Gemcitabine Hydrochloride
  • Nivolumab
  • Ipilimumab
  • Gemcitabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Vincent Chung, MD specialize in?

Is Vincent Chung, MD currently recruiting for clinical trials?

Are there any treatments that Vincent Chung, MD has studied deeply?

What is the best way to schedule an appointment with Vincent Chung, MD?

What is the office address of Vincent Chung, MD?

Is there any support for travel costs?